Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Melanoma × romiplostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocytopenia 4 Lymphoma, Non-Hodgkin 4 Multiple Myeloma 3 Hodgkin Disease 2 Solid Tumor 1 Sarcoma, Ewing 1 Ovarian Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Leukemia, Monocytic, Acute 1 Leukemia, Lymphoid 1 Hematologic Neoplasms 1 Glioblastoma 1

Interventions

Nivolumab 130 Ipilimumab 122 pembrolizumab 110 Cyclophosphamide 72 Interleukin-2 60 aldesleukin 57 Temozolomide 40 Radiosurgery 36 trametinib 34 Vemurafenib 34 Biopsy 32 fludarabine 31 Blood Specimen Collection 31 dabrafenib 30 Radiotherapy 30 fludarabine phosphate 27 sargramostim 26 Bevacizumab 25 Introns 21 Magnetic Resonance Spectroscopy 20 Dacarbazine 20 encorafenib 17 cobimetinib 17 binimetinib 17 Specimen Handling 17 Granulocyte-Macrophage Colony-Stimulating Factor 17 Paclitaxel 16 Cisplatin 16 incomplete Freund's adjuvant 14 montanide ISA 51 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡